182 related articles for article (PubMed ID: 33618687)
21. Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors.
Jahnke K; Thiel E; Martus P; Herrlinger U; Weller M; Fischer L; Korfel A;
J Neurooncol; 2006 Nov; 80(2):159-65. PubMed ID: 16699873
[TBL] [Abstract][Full Text] [Related]
22. STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in primary central nervous system lymphoma.
Mondello P; Cuzzocrea S; Arrigo C; Pitini V; Mian M; Bertoni F
Hematol Oncol; 2020 Feb; 38(1):106-110. PubMed ID: 31524297
[No Abstract] [Full Text] [Related]
23. Prognostic Value of CSF IL-10 at Early Assessment of Induction Chemotherapy in Primary CNS Lymphomas: A LOC Network Study.
Herzi D; Le Garff-Tavernier M; Sourdeau E; Choquet S; Soussain C; Nichelli L; Mathon B; Mokhtari K; Laurenge A; Alentorn A; Boussen I; Alcantara M; Hoang-Xuan K; Houillier C
Neurology; 2024 Jun; 102(12):e209527. PubMed ID: 38830184
[TBL] [Abstract][Full Text] [Related]
24. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.
Soussain C; Choquet S; Blonski M; Leclercq D; Houillier C; Rezai K; Bijou F; Houot R; Boyle E; Gressin R; Nicolas-Virelizier E; Barrie M; Moluçon-Chabrot C; Lelez ML; Clavert A; Coisy S; Leruez S; Touitou V; Cassoux N; Daniau M; Ertault de la Bretonnière M; El Yamani A; Ghesquières H; Hoang-Xuan K
Eur J Cancer; 2019 Aug; 117():121-130. PubMed ID: 31279304
[TBL] [Abstract][Full Text] [Related]
25. Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma.
del Rio MS; Choquet S; Hoang-Xuan K; Glaisner S; Fourme E; Janvier M; Soussain C
J Neurooncol; 2011 Nov; 105(2):409-14. PubMed ID: 21656329
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of interleukin-10 concentration in the cerebrospinal fluid of patients with primary central nervous system lymphoma.
Geng M; Song Y; Xiao H; Wu Z; Deng X; Chen C; Wang G
Oncol Lett; 2021 Jan; 21(1):2. PubMed ID: 33240408
[TBL] [Abstract][Full Text] [Related]
27. A single-center retrospective analysis of outcome measures and consolidation strategies for relapsed and refractory primary CNS lymphoma.
Bonm AV; Gibson AW; Holmberg LA; Mielcarek M; McGranahan T; Taylor LP; Graber JJ
J Neurooncol; 2021 Jan; 151(2):193-200. PubMed ID: 33398532
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemistry for c-myc and bcl-2 overexpression improves risk stratification in primary central nervous system lymphoma.
Hatzl S; Posch F; Deutsch A; Beham-Schmid C; Stöger H; Greinix H; Pichler M; Neumeister P; Prochazka KT
Hematol Oncol; 2020 Aug; 38(3):277-283. PubMed ID: 32101329
[TBL] [Abstract][Full Text] [Related]
29. Multi-marker algorithms based on CXCL13, IL-10, sIL-2 receptor, and β2-microglobulin in cerebrospinal fluid to diagnose CNS lymphoma.
Maeyama M; Sasayama T; Tanaka K; Nakamizo S; Tanaka H; Nishihara M; Fujita Y; Sekiguchi K; Kohta M; Mizukawa K; Hirose T; Itoh T; Kohmura E
Cancer Med; 2020 Jun; 9(12):4114-4125. PubMed ID: 32314548
[TBL] [Abstract][Full Text] [Related]
30. Intraocular involvement is associated with a high risk of disease relapse in primary central nervous system lymphoma.
Zhuang L; Lai J; Chen K; Ding T; Yuan Y; Ma Y; Kang H; Lin Z; Fan N; Ma J; Zeng Q; Xu X; Wang Q; Chen B
Oncol Rep; 2019 Jan; 41(1):397-404. PubMed ID: 30320386
[TBL] [Abstract][Full Text] [Related]
31. Increased levels of CSF soluble CD27 in patients with primary central nervous system lymphoma.
Murase S; Saio M; Takenaka K; Shinoda J; Nishimura Y; Sakai N; Takami T
Cancer Lett; 1998 Oct; 132(1-2):181-6. PubMed ID: 10397472
[TBL] [Abstract][Full Text] [Related]
32. Primary central nervous system lymphoma with systemic metastasis: case report and review.
Brown MT; McClendon RE; Gockerman JP
J Neurooncol; 1995; 23(3):207-21. PubMed ID: 7673983
[TBL] [Abstract][Full Text] [Related]
33. CSF interleukin 6 is a useful marker to distinguish pseudotumoral CNS inflammatory diseases from primary CNS lymphoma.
Ungureanu A; Le Garff-Tavernier M; Costopoulos M; Parratte T; Brinet A; Durand H; Gaultier C; Hurstel R; Alamome I; Sellal F; Ahle G
J Neurol; 2021 Aug; 268(8):2890-2894. PubMed ID: 33609156
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS.
Baraniskin A; Chomiak M; Ahle G; Gress T; Buchholz M; Turewicz M; Eisenacher M; Margold M; Schlegel U; Schmiegel W; Hahn S; Schroers R
J Neurooncol; 2018 May; 137(3):463-468. PubMed ID: 29327175
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic utility of CSF soluble CD27 for primary central nervous system lymphoma in immunocompetent patients.
Murase S; Saio M; Andoh H; Takenaka K; Shinoda J; Nishimura Y; Sakai N; Takami T
Neurol Res; 2000 Jul; 22(5):434-42. PubMed ID: 10935213
[TBL] [Abstract][Full Text] [Related]
36. Ex vivo NMR metabolomics approach using cerebrospinal fluid for the diagnosis of primary CNS lymphoma: Correlation with MR imaging characteristics.
Kim JH; An YJ; Kim TM; Kim JE; Park S; Choi SH
Cancer Med; 2023 Feb; 12(4):4679-4689. PubMed ID: 35941814
[TBL] [Abstract][Full Text] [Related]
37. CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma.
Viaccoz A; Ducray F; Tholance Y; Barcelos GK; Thomas-Maisonneuve L; Ghesquières H; Meyronet D; Quadrio I; Cartalat-Carel S; Louis-Tisserand G; Jouanneau E; Guyotat J; Honnorat J; Perret-Liaudet A
Neuro Oncol; 2015 Nov; 17(11):1497-503. PubMed ID: 26014047
[TBL] [Abstract][Full Text] [Related]
38. Pretreatment dynamic contrast-enhanced MRI biomarkers correlate with progression-free survival in primary central nervous system lymphoma.
Hatzoglou V; Oh JH; Buck O; Lin X; Lee M; Shukla-Dave A; Young RJ; Peck KK; Vachha B; Holodny AI; Grommes C
J Neurooncol; 2018 Nov; 140(2):351-358. PubMed ID: 30073640
[TBL] [Abstract][Full Text] [Related]
39. Interleukin 10 Level in the Cerebrospinal Fluid as a Possible Biomarker for Lymphomatosis Cerebri.
Hashiguchi S; Momoo T; Murohashi Y; Endo M; Shimamura M; Kawasaki T; Kanada S; Nozawa A; Tada M; Koyano S; Tanaka F
Intern Med; 2015; 54(12):1547-52. PubMed ID: 26073248
[TBL] [Abstract][Full Text] [Related]
40. [Case of primary intraocular central nervous system lymphoma with high interleukin 10 level and positive cytology in cerebrospinal fluid].
Hideyama T; Tanaka H; Uesaka Y; Kunimoto M; Miwa A
Rinsho Shinkeigaku; 2008 Jun; 48(6):415-8. PubMed ID: 18616153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
